FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes

被引：3
|
作者：
Montesinos, Pau [1 ]
de la Rubia, Javier [1 ]
Orti, Guillermo [1 ]
Sanz, Jaime [1 ]
Martinez, David [1 ]
Mendoza, Ninotchka [2 ]
Scaff, Miguel [1 ]
Paciello, Mariliz [1 ]
Romero, Monica [1 ]
Martin, Guillermo [1 ]
Lorenzo, Ignacio [1 ]
Martinez, Jesus [1 ]
Algarra, Lorenzo [1 ]
Jarque, Isidro [1 ]
Perez-Sirvent, Mariluz [1 ]
Sanz, Guillermo [1 ]
Sanz, Miguel A. [1 ]
机构：
[1] Hosp Univ La Fe, Valencia, Spain
[2] CSS Arnulfo Arias Madrid, Panama City, Panama
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2866.2866
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2866
引用
收藏
页码：843A / 843A
页数：1
相关论文
共 50 条
  • [1] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies
    de la Rubia, J
    Regadera, AI
    Martín, G
    Cervera, J
    Sanz, G
    Martínez, JA
    Jarque, I
    García, I
    Andreu, R
    Moscardó, F
    Jiménez, C
    Mollá, S
    Benlloch, L
    Sanz, MA
    LEUKEMIA RESEARCH, 2002, 26 (08) : 725 - 730
  • [2] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia
    Parker, JE
    Pagliuca, A
    Mijovic, A
    Cullis, JO
    Czepulkowski, B
    Rassam, SMB
    Samartunga, IR
    Grace, R
    Gover, PA
    Mufti, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) : 939 - 944
  • [3] Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-Ida) for the treatment of high risk myeloid malignancies
    Parker, JE
    Cullis, JO
    Mijovic, A
    Pagliuca, A
    Mufti, GJ
    BLOOD, 1996, 88 (10) : 1803 - 1803
  • [4] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
    Yalman, N
    Sarper, N
    Devecioglu, Ö
    Anak, S
    Eryilmaz, E
    Can, M
    Yenilmez, H
    Agaoglu, L
    Gedikoglu, G
    TURKISH JOURNAL OF PEDIATRICS, 2000, 42 (03) : 198 - 204
  • [5] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
    Xueya Zhang
    Xizhe Guo
    Annals of Hematology, 2019, 98 : 2223 - 2225
  • [6] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
    Zhang, Xueya
    Guo, Xizhe
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2223 - 2225
  • [7] Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of high risk myelodysplastic syndromes (MDS).
    Ferrara, F
    Mirto, S
    Montillo, M
    Mele, G
    Tedeschi, A
    Ciolli, S
    Annunziata, M
    Copia, C
    Magrin, S
    Leoni, F
    BLOOD, 1997, 90 (10) : 371 - 371
  • [8] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
    Montillo, M
    Mirto, S
    Petti, MC
    Latagliata, R
    Magrin, S
    Pinto, A
    Zagonel, V
    Mele, G
    Tedeschi, A
    Ferrara, F
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 58 (02) : 105 - 109
  • [9] Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (FLAG regimen): A single center study
    Carella, AM
    Cascavilla, N
    Greco, MM
    Melillo, L
    Sajeva, MR
    Ladogana, S
    D'Arena, G
    Perla, G
    Carotenuto, M
    LEUKEMIA & LYMPHOMA, 2001, 40 (3-4) : 295 - 303
  • [10] Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)
    Borthakur, Gautam M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jabbour, Elias
    Patel, Keyur
    Issa, Ghayas C.
    Daver, Naval G.
    Ohanian, Maro N.
    Brandt, Mark
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
12345